SCHEMBL4465488

SCHEMBL4465488

Cc1cc(C)c2c(C#N)c(C=CC(=O)Nc3cccnc3)n(Cc3cccnc3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.41
ALDH1A1 P00352 7/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
HPGD P15428 2/20 0.41
BLM P54132 1/20 0.41
NPC1 O15118 9/20 0.40
KDM4E B2RXH2 6/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
CASP1 P29466 2/20 0.38
HSD17B10 Q99714 2/20 0.38
AR P10275 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
CASP7 P55210 1/20 0.38
PKM P14618 1/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465484 1.00 RAB9A (0.41) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4472528 0.96 RAB9A (0.44) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4472521 0.96 RAB9A (0.44) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4477465 0.88 RAB9A (0.47) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4477459 0.88 RAB9A (0.47) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4487020 0.88 AR (0.41) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL4487025 0.88 AR (0.41) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL4479081 0.86 RAB9A (0.43) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4479073 0.86 RAB9A (0.43) RAB9AALDH1A1SMN1; SMN2HPGDBLM
SCHEMBL4473588 0.84 RAB9A (0.41) RAB9AALDH1A1SMN1; SMN2HPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582651-B2 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-01 US disclosed
US-20060167038-A1 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
EP-1535922-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167038-A1 Pyrrolopyridine derivative and use thereof OPRD1, TRPV1, OPRM1 RAB9A 3079/4885ALDH1A1 1363/4885SMN1; SMN2 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.